Evidence-based sample size calculations based upon updated meta-analysis

Statistics in Medicine

Volumn 26, Issue 12, 2007, Pages 2479-2500

  Sutton, Alexander J ^a   Cooper, Nicola J ^a   Jones, David R ^a   Lambert, Paul C ^a   Thompson, John R ^a   Abrams, Keith R ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cumulative meta analysis; Evidence based medicine; Meta analysis; Power; Random effects; Sample size

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; ASSAY; CALCULATION; CLINICAL TRIAL; COCHRANE LIBRARY; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; EVIDENCE BASED MEDICINE; HUMAN; HYBRID; HYPOTHESIS; META ANALYSIS; MONTE CARLO METHOD; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SENSITIVITY ANALYSIS; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VARIANCE;

ANTI-BACTERIAL AGENTS; BAYES THEOREM; COMMON COLD; COMPUTER SIMULATION; HUMANS; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; SAMPLE SIZE;

EID: 34249029357     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2704     Document Type: Article

References (39)

1. Whitehead A. Meta-analysis of Controlled Clinical Trials. Wiley: Chichester, 1993; 1-336.
2. Carpenter LM. Is the study worth doing? The Lancet 1993; 342:221-223.
3. Cooper NJ, Jones DR, Sutton AJ. The use of systematic reviews when designing new studies. Clinical Trials 2005; 2:260-264.
4. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Wiley: Chichester, 2003; 1-391.
5. O'Hagan A, Stevens JW, Campbell MJ. Assurance in clinical trial design. Pharmaceutical Statistics 2005; 4:187-201.
6. Feiveson AH. Power by simulation. The Stata Journal 2002; 2:107-124.
7. Sutton AJ, Abrams KR, Jones DR et al. Methods for Meta-analysis in Medical Research. Wiley: Chichester, 2000; 1-317.
8. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. British Medical Journal 1994; 309:1351-1355.
9. Bradburn MJ, Deeks JJ, Altman DG. Metan - an alternative meta-analysis command. Stata Technical Bulletin 1998; STB 44:sbe24:4-sbe24:15.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7:177-188.
11. Hardy RJ, Thompson SG. A likelihood approach to meta-analysis with random effects. Statistics in Medicine 1996; 15:619-629.
12. Biggerstaff BJ, Tweedie RL. Incorporating variability in estimates of heterogeneity in the random effects model in meta-analysis. Statistics in Medicine 1997; 16:753-768.
13. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Statistics in Medicine 1995; 14:2685-2699.
14. Lambert P, Sutton AJ, Burton P, Abrams KR, Jones DR. How vague is vague? Assessment in the use of vague prior distributions for variance components. Statistics in Medicine 2005; 24:2401-2428.
15. Spiegelhalter DJ, Thomas A, Best NG. WinBUGS Version 1.4. User Manual. MRC Biostatistics Unit: Cambridge, 2000.
16. Higgins JPT, Spiegelhalter DJ, Thompson SG. Random effects meta-analysis: important questions and Bayesian solutions, manuscript.
17. Parmar MKB, Ungerleider RS, Simon R. Assessing whether to perform a confirmatory randomized clinical trial. Journal of the National Cancer institute 1996; 88:1645-1651.
18. Fletcher AE, Spiegelhalter DJ, Staessen JA et al. Implications for trials in progress of publication of positive results. The Lancet 1993; 342:653-656.
19. Alderson P. Claims of "no difference" or "no effect". Cochrane News 2002 (http://www.cochrane.org/newslett/ ccnews26.pdf). Last accessed 23rd September 2005.
20. Arroll B, Kenealy T. Antibiotics Versus Placebo for the Common Cold (Cochrane Review), in the Cochrane Library Issue 2. Oxford, 1999 (Updated Software).
21. Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Statistics in Medicine 1998; 17:841-856.
22. Higgins JPT, Thompson SG. Quantifying heterogeneity in meta-analysis. Statistics in Medicine 2002; 21:1539-1558.
23. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003; 327:557-560.
24. Lambert P, Sutton AJ, Abrams KR, Jones DR. A comparison of summary patient level covariates in meta-regression with individual patient data meta-analyses. Journal of Clinical Epidemiology 2002; 55:86-94.
25. Pogue JM, Yousuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clinical Trials 1997; 18:580-593.
26. Hedges LV, Pigott TD. The power of statistical tests in meta-analysis. Psychological Methods 2001; 6:203-217.
27. Muncer SJ, Taylor S, Craigie M. Power dressing and meta-analysis: incorporating power analysis into meta-analysis. Journal of Advanced Nursing 2002; 38:274-280.
28. Muncer SJ. Power dressing is important in meta-analysis (Letter). British Medical Journal 1999; 318:870-871.
29. Margitic SE, Morgan TM, Sager MA, Furberg CD. Lessons learned from a prospective meta-analysis. Journal of the American Geriatrics Society 1995; 43:435-439.
30. Senn S. The many modes of meta. Drug Information Journal 2000; 34:535-549.
31. Fedorov V, Jones B, Rockhold F. The design and analysis of multicentre trials in the random effects setting. Glaxo SmithKline BDS Technical Report 2002-03, 2002.
32. O'Hagan A, Stevens JW. Bayesian assessment of sample size for clinical trials of cost effectiveness. Medical Decision Making 2001; 21:219-230.
33. Ades AE, Lu G, Higgins JPT. The interpretation of random-effects meta-analysis in decision models. Medical Decision Making 2005; 25:646-654.
34. Van Houwelingen HC, Zwinderman KH, Stijnen T. A bivariate approach to meta-analysis. Statistics in Medicine 1993; 12:2273-2284.
35. van Houwelingen HC, Arends LR, Stijnen T. Tutorial in biostatistics. Advanced methods in meta-analysis: multivariate approach and meta-regression. Statistics in Medicine 2002; 21:589-624.
36. Whitehead A. Meta-analysis of Controlled Clinical Trials. Sequential Methods for Meta-analysis (Chapter 12). Wiley: Chichester, England, 2002; 285-303.
37. Claxton K. Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Economics 1999; 8:269-274.
38. Lindley DV. The choice of sample size. Journal of the Royal Statistical Society, Series D - The Statistician 1997; 46:129-138.
39. Berry DA. In Discussion of 'Bayesian approaches to randomized trials' by Spiegelhalter DJ et al. Journal of the Royal Statistical Society, Series A - General 1994; 157:387-416.